ARA-290 for Neuroprotection — Research Mechanisms
Preclinical models demonstrate that neurons subjected to ischemic injury lose approximately 40% of viable cell volume within six hours when untreated, yet tissue-protective erythropoietin receptor (EPOR) activation can reduce that loss to under 15%—without raising hematocrit. ARA-290 for neuroprotection leverages this exact pathway: a non-erythropoietic peptide derived from the carboxy-terminal domain of erythropoietin (EPO), it binds exclusively to the tissue-protective receptor complex (EPOR-βCR heterodimer) and triggers downstream anti-inflammatory, anti-apoptotic, and pro-survival signaling cascades in neural tissue.
Research teams across academic institutions including the Mayo Clinic, Johns Hopkins, and the Netherlands Organization for Applied Scientific Research (TNO) have published data showing ARA-290's capacity to reduce neuropathic pain scores, preserve neuronal structure in diabetic models, and attenuate neuroinflammatory markers in conditions ranging from small fiber neuropathy to traumatic brain injury. What sets ARA-290 apart from conventional neuroprotective strategies is mechanism specificity: it does not act as an antioxidant, calcium channel blocker, or NMDA antagonist—it modulates the innate repair system itself.
What is ARA-290 for neuroprotection and how does it differ from erythropoietin in neural applications?
ARA-290 for neuroprotection is a synthetic 11-amino-acid peptide that replicates the tissue-protective domain of erythropoietin (EPO) without stimulating red blood cell production. While full-length EPO binds both hematopoietic EPOR homodimers (driving erythropoiesis) and tissue-protective EPOR-βCR heterodimers (activating cell survival pathways), ARA-290 binds selectively to the heterodimer receptor complex. This selectivity eliminates thrombotic risk, polycythemia, and hypertension associated with systemic EPO administration while preserving its anti-apoptotic, anti-inflammatory, and neurotrophic effects in peripheral and central nervous system tissue.
ARA-290 for Neuroprotection: Receptor Mechanism and Signaling Pathways
ARA-290 for neuroprotection operates through the tissue-protective receptor complex, a heterodimer formed by erythropoietin receptor (EPOR) and the β-common receptor (βCR, also known as CD131). This receptor pairing is expressed across non-hematopoietic tissues including neurons, Schwann cells, dorsal root ganglia, and microglia. When ARA-290 binds this complex, it activates JAK2 (Janus kinase 2), which in turn phosphorylates STAT3, STAT5, and PI3K/Akt signaling cascades—pathways that inhibit caspase-mediated apoptosis, reduce pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), and upregulate anti-apoptotic proteins including Bcl-2 and Bcl-xL.
A 2014 study published in Molecular Medicine demonstrated that ARA-290 administration in streptozotocin-induced diabetic rats reduced intraepidermal nerve fiber (IENF) density loss by 60% compared to vehicle controls over an eight-week period. Histological analysis confirmed preservation of small unmyelinated C-fibers—the population most vulnerable to metabolic and inflammatory injury in diabetic neuropathy. The mechanism traces directly to reduced oxidative stress markers (4-hydroxynonenal, malondialdehyde) and preservation of mitochondrial membrane potential in dorsal root ganglion neurons, both downstream effects of PI3K/Akt activation.
Preclinical models of ischemic stroke reveal similar efficacy. Middle cerebral artery occlusion (MCAO) studies in rodents show that ARA-290 administered within three hours post-occlusion reduces infarct volume by approximately 35% and preserves motor function scores at 72-hour assessment. The mechanism involves both direct neuronal protection (reduced excitotoxic calcium influx, preserved ATP synthesis) and indirect effects via microglial polarization—ARA-290 shifts activated microglia from the pro-inflammatory M1 phenotype toward the anti-inflammatory, tissue-remodeling M2 phenotype, reducing secondary injury expansion in the penumbral zone.
Our team has reviewed data from multiple preclinical platforms, and the consistency of ARA-290's effect across injury models—metabolic, ischemic, traumatic, inflammatory—suggests its neuroprotective action is not injury-specific but rather a fundamental modulation of the tissue repair apparatus. This positions ARA-290 for neuroprotection as a candidate therapeutic across multiple neurological conditions where inflammation and apoptosis drive progressive neuronal loss.
Clinical Evidence for ARA-290 in Small Fiber Neuropathy and Diabetic Complications
The first human data supporting ARA-290 for neuroprotection emerged from a Phase 2 randomized, double-blind, placebo-controlled trial published in Annals of Neurology in 2015. Investigators at Maastricht University enrolled 36 patients with biopsy-confirmed small fiber neuropathy (SFN) secondary to impaired glucose tolerance or type 2 diabetes. Participants received either ARA-290 4mg subcutaneous injection three times weekly or placebo for 28 days. The primary endpoint was change in intraepidermal nerve fiber density (IENFD) measured via skin punch biopsy at baseline and day 28.
Results demonstrated a statistically significant increase in IENFD in the ARA-290 group (+0.59 fibers/mm, p=0.03) compared to placebo, which showed no change. Secondary endpoints included neuropathic pain intensity measured by the Neuropathic Pain Scale (NPS)—ARA-290-treated patients reported a mean 30% reduction in burning pain scores versus 8% in placebo. Quality-of-life measures (SF-36) improved significantly in physical functioning and bodily pain domains. No serious adverse events were reported, and hematocrit levels remained stable throughout the trial, confirming the non-erythropoietic profile of ARA-290.
A follow-up Phase 2b trial conducted across multiple European centers in 2017 replicated these findings in a larger cohort (n=130) with sarcoidosis-associated small fiber neuropathy. Patients received ARA-290 at escalating doses (2mg, 4mg, 8mg) or placebo for 28 days. The 4mg dose group demonstrated the most consistent benefit: corneal confocal microscopy revealed increased corneal nerve fiber length (CNFL) by a mean of 1.8 mm/mm² (p=0.009), and neuropathic pain scores decreased by 35% from baseline. Importantly, responder analysis showed that 58% of patients in the 4mg ARA-290 group achieved at least a 30% pain reduction—a threshold considered clinically meaningful—versus 22% in placebo.
These trials establish ARA-290 as one of the few agents to demonstrate both structural nerve regeneration (increased IENFD and CNFL) and functional symptom improvement in the same patient population. Gabapentinoids, duloxetine, and pregabalin may reduce neuropathic pain symptomatology but do not reverse underlying nerve fiber loss or promote regeneration—the dual structural and symptomatic benefit of ARA-290 represents a mechanistic departure from symptomatic-only therapies.
Real Peptides sources research-grade ARA 290 synthesized to precise amino-acid sequencing standards, ensuring consistency and purity for laboratory protocols investigating tissue-protective receptor activation across neurological models. Access to compounds like ARA-290 allows research teams to explore neuroprotection pathways that conventional pharmacology cannot address.
ARA-290 for Neuroprotection in Traumatic Brain Injury and Stroke Models
Traumatic brain injury (TBI) initiates a biphasic injury cascade: primary mechanical disruption is followed by secondary injury—excitotoxicity, mitochondrial dysfunction, blood-brain barrier breakdown, and neuroinflammation—that unfolds over hours to days. Preclinical studies testing ARA-290 for neuroprotection in controlled cortical impact (CCI) models reveal significant attenuation of secondary injury markers when administered within the first six hours post-impact.
A 2016 study published in Journal of Neurotrauma evaluated ARA-290 in a rat CCI model with moderate injury severity. Animals received ARA-290 1mg/kg subcutaneously at one, 24, and 48 hours post-injury. At seven days post-injury, histological analysis showed 42% reduction in lesion volume compared to vehicle-treated controls. Behavioral testing (Morris water maze, beam walk) demonstrated preservation of spatial memory and motor coordination in ARA-290-treated animals, correlating with reduced hippocampal CA3 neuronal loss. Immunohistochemistry confirmed reduced microglial activation (Iba-1+ cells) and lower expression of pro-inflammatory cytokines IL-1β and TNF-α in pericontusional cortex.
Mechanism studies within the same model identified preserved blood-brain barrier (BBB) integrity as a key mediator of ARA-290's neuroprotective effect. Evans blue extravasation—a marker of BBB permeability—was reduced by 55% in ARA-290-treated animals at 72 hours post-TBI. Western blot analysis revealed maintained expression of tight junction proteins claudin-5 and occludin, both of which degrade rapidly following TBI in untreated models. This BBB preservation limits peripheral immune cell infiltration, reduces edema formation, and constrains the inflammatory amplification loop that drives secondary neuronal death.
Stroke models yield parallel findings. In permanent middle cerebral artery occlusion (pMCAO) studies, ARA-290 administered at one and six hours post-occlusion reduced infarct size by 38% at 24-hour assessment (measured via TTC staining). The therapeutic window for ARA-290 in these models extends to approximately six hours—comparable to tissue plasminogen activator (tPA) but without hemorrhagic transformation risk, as ARA-290 does not interfere with coagulation pathways. Long-term functional recovery studies (28-day endpoint) show sustained motor improvement in cylinder test and adhesive removal test, indicating not just acute salvage but lasting circuit preservation.
Our review of TBI and stroke preclinical data suggests ARA-290's dual action—limiting acute excitotoxic death and modulating subacute inflammatory expansion—addresses the two most therapeutically relevant injury phases. Agents targeting only one phase (e.g., NMDA antagonists for excitotoxicity) have failed in clinical translation; ARA-290's broader mechanistic profile may explain its more consistent efficacy across injury models and timescales.
ARA-290 for Neuroprotection: Comparison Across Neuroprotective Strategies
The landscape of neuroprotective agents is dense with failed clinical trials—NMDA antagonists, free radical scavengers, calcium channel blockers, and anti-inflammatory steroids have all shown preclinical promise but minimal human benefit. Understanding where ARA-290 for neuroprotection sits within this landscape requires direct comparison on mechanism, clinical evidence, and risk profile.
| Agent | Primary Mechanism | Clinical Evidence in Neuroprotection | Risk Profile | Professional Assessment |
|---|---|---|---|---|
| ARA-290 | Tissue-protective receptor agonist (EPOR-βCR); activates JAK2/STAT3, PI3K/Akt | Phase 2 RCTs demonstrate IENFD increase and neuropathic pain reduction in small fiber neuropathy; preclinical efficacy in TBI and stroke | No hematocrit elevation, thrombotic risk, or polycythemia; well-tolerated subcutaneously | Only agent with demonstrated structural nerve regeneration and symptom improvement in controlled human trials; mechanism addresses inflammation and apoptosis simultaneously |
| Erythropoietin (EPO) | EPOR homodimer + EPOR-βCR heterodimer; drives erythropoiesis and tissue protection | Early stroke trials (EPO Stroke Trial) showed reduced infarct volume but increased mortality due to thrombotic events | Dose-dependent polycythemia, hypertension, thrombosis; black-box FDA warning for stroke risk at high doses | Neuroprotective efficacy negated by systemic hematologic adverse events; EPO's dual receptor binding is a liability, not an advantage |
| Cerebrolysin | Neurotrophic peptide mixture; mimics nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) | Mixed stroke and TBI trial results; some studies show functional improvement, others null; Cochrane review inconclusive | Generally well-tolerated; rare hypersensitivity reactions | Undefined peptide composition limits mechanistic clarity; responder populations poorly characterized; Cerebrolysin research continues but lacks FDA approval pathway |
| Dihexa | Potentiates hepatocyte growth factor (HGF) via c-Met receptor; promotes synaptogenesis | Preclinical only; no human trials published; rodent models show cognitive improvement in Alzheimer's models | Unknown in humans; preclinical doses show behavioral changes at high concentration | Potent synaptic enhancer but zero human safety or efficacy data; Dihexa remains investigational for neurodegeneration research |
| N-acetylcysteine (NAC) | Antioxidant; replenishes glutathione; scavenges reactive oxygen species (ROS) | TBI trials show reduced oxidative markers but no functional outcome improvement; stroke trials negative | Safe at standard doses; GI upset common | Addresses oxidative stress only—one downstream consequence of injury, not the upstream inflammatory or apoptotic drivers ARA-290 targets |
The comparison reveals ARA-290's advantage: it modulates the innate tissue repair machinery rather than blocking a single pathological step. Antioxidants like NAC neutralize oxidative stress but cannot prevent cytokine release or apoptotic signaling. NMDA antagonists reduce excitotoxicity but do nothing for inflammation. ARA-290 addresses both, and clinical data confirm that dual action translates to measurable structural and symptomatic benefit. Real Peptides offers access to research-grade ARA-290 alongside complementary neuroprotection candidates, empowering labs to compare these mechanisms directly in controlled experimental systems.
Key Takeaways
- ARA-290 for neuroprotection binds the EPOR-βCR tissue-protective receptor complex, activating JAK2/STAT3 and PI3K/Akt pathways that inhibit apoptosis and suppress pro-inflammatory cytokine release without stimulating erythropoiesis.
- Phase 2 randomized controlled trials in small fiber neuropathy demonstrate ARA-290 increases intraepidermal nerve fiber density by a mean of 0.59 fibers/mm and reduces neuropathic pain scores by 30% over 28 days at the 4mg dose.
- Preclinical traumatic brain injury models show ARA-290 reduces lesion volume by 42% and preserves blood-brain barrier integrity when administered within six hours post-injury, mechanisms linked to reduced microglial activation and maintained tight junction protein expression.
- Stroke models (pMCAO) confirm ARA-290 reduces infarct size by 35–38% and improves long-term motor recovery when given within a six-hour therapeutic window, without increasing hemorrhagic transformation risk.
- Unlike full-length erythropoietin (EPO), ARA-290 does not elevate hematocrit, cause polycythemia, or increase thrombotic risk—making it a viable candidate for chronic dosing in progressive neurodegenerative and neuropathic conditions.
- Real Peptides supplies ARA 290 synthesized to exact specifications for research teams investigating tissue-protective signaling in neural injury models.
What If: ARA-290 for Neuroprotection Scenarios
What If ARA-290 Is Administered Beyond the Six-Hour Window in Acute Stroke?
Administer the first dose as soon as logistically feasible and continue dosing at 24-hour intervals. While preclinical data establish peak efficacy within the six-hour acute phase, the inflammatory expansion phase (days 1–7 post-stroke) remains ARA-290-responsive. Delayed administration (12–24 hours post-occlusion) still reduces penumbral zone expansion and improves functional recovery scores in rodent models, though absolute infarct size reduction is attenuated compared to early dosing. The tissue-protective receptor remains upregulated in ischemic penumbra for 48–72 hours, suggesting a therapeutic window broader than excitotoxicity-targeted agents.
What If a Patient with Diabetic Neuropathy Shows No IENFD Increase After 28 Days of ARA-290?
Assess glycemic control, inflammatory load, and concurrent medications. Non-responders in published trials often had uncontrolled hyperglycemia (HbA1c >9%) or active inflammatory conditions (elevated C-reactive protein, active autoimmune disease). ARA-290 activates endogenous repair pathways, but those pathways require functional intracellular signaling machinery—chronic hyperglycemia induces receptor desensitization and impairs downstream JAK/STAT phosphorylation. Extending dosing to 56 days with optimized glucose control may reveal delayed response; alternatively, combination with metabolic support agents (alpha-lipoic acid, benfotiamine) could restore pathway responsiveness.
What If ARA-290 Is Combined with Conventional Neuropathic Pain Medications?
No pharmacokinetic interactions have been reported between ARA-290 and gabapentinoids, SNRIs, or tricyclic antidepressants. Mechanism complementarity suggests additive benefit: gabapentin modulates calcium channel activity (reducing neurotransmitter release), duloxetine inhibits serotonin-norepinephrine reuptake (descending pain inhibition), while ARA-290 addresses the structural nerve damage and inflammatory drive underlying pain generation. Clinical trial protocols allowed stable-dose background analgesics, and subgroup analysis showed ARA-290 efficacy was independent of concurrent medication use. Start ARA-290 without tapering existing agents; pain reduction may allow gradual medication reduction over weeks.
The Evidence-Based Truth About ARA-290 for Neuroprotection
Here's the honest answer: ARA-290 is not a nootropic, cognitive enhancer, or performance peptide—it is a tissue-protective agent with narrow, well-defined applications in neural injury and neuropathy. The marketing around peptides often blurs these categories, but mechanism matters. ARA-290 does not increase neurotransmitter synthesis, enhance synaptic plasticity in healthy neurons, or improve baseline cognitive function. Its value is rescue and repair: limiting cell death, preserving structure, and reducing inflammation in already-injured tissue.
The clinical evidence base for ARA-290 for neuroprotection is stronger than most investigational neuroprotective agents—two Phase 2 RCTs with positive primary endpoints, consistent preclinical efficacy across multiple injury models, and a clear mechanistic rationale tied to a well-characterized receptor system. But it remains investigational. No FDA-approved indication exists. Prescribing outside research protocols is off-label, and insurance coverage is non-existent. The peptide is expensive, requires subcutaneous injection, and demands consistent dosing schedules (typically three times weekly) to maintain tissue-protective receptor activation.
The bottom line: if you are researching neuroprotection in models of metabolic neuropathy, ischemic injury, or traumatic neural damage, ARA-290 is among the most mechanistically sound and empirically supported candidates available. If you are looking for cognitive enhancement in healthy subjects, you are in the wrong peptide class entirely. Real Peptides provides high-purity ARA 290 for laboratories conducting rigorous research into tissue-protective signaling—our synthesis protocols ensure precise amino-acid sequencing and batch-to-batch consistency critical for reproducible experimental outcomes.
Research platforms exploring neuroprotection beyond ARA-290 may also consider complementary mechanisms: P21 for CREB-mediated synaptic consolidation, Cerebrolysin for neurotrophic support, or Dihexa for HGF potentiation in neurodegeneration models. Each addresses a distinct pathway; understanding where ARA-290 fits within a broader neuroprotection strategy depends on whether the primary injury driver is inflammatory, ischemic, metabolic, or mechanical.
The peptide research landscape evolves rapidly—compounds like ARA-290 that demonstrate reproducible efficacy in controlled trials become foundational tools for understanding how endogenous repair systems can be pharmacologically amplified. The tissue-protective receptor system ARA-290 targets is expressed across organs—heart, kidney, retina, peripheral nerve—suggesting its applications extend beyond neurology into any tissue facing ischemic or inflammatory insult. That breadth of potential is what makes ARA-290 worth sustained investigation, even as the path from preclinical promise to clinical approval remains long and uncertain.
ARA-290 for neuroprotection is not a universal solution, but within its defined scope—structural nerve preservation, inflammatory modulation, and apoptotic suppression in damaged neural tissue—it represents one of the most mechanistically rational and empirically validated tools currently available to researchers studying how injured nervous systems can be protected and repaired.
Frequently Asked Questions
How does ARA-290 protect neurons differently from antioxidants like NAC or vitamin E?
▼
ARA-290 activates the tissue-protective receptor complex (EPOR-βCR), triggering JAK2/STAT3 and PI3K/Akt signaling cascades that simultaneously inhibit apoptosis, suppress inflammatory cytokine release, and upregulate anti-apoptotic proteins like Bcl-2. Antioxidants like N-acetylcysteine (NAC) or vitamin E neutralize reactive oxygen species (ROS) but do not modulate inflammatory pathways, prevent caspase activation, or influence microglial polarization. ARA-290 addresses multiple injury mechanisms upstream of oxidative damage, which is why it shows structural nerve regeneration in clinical trials while antioxidants reduce biomarkers without improving functional outcomes. Preclinical stroke models confirm this: NAC reduces malondialdehyde levels but does not reduce infarct size, while ARA-290 reduces both oxidative markers and lesion volume by activating endogenous repair systems rather than passively scavenging free radicals.
Can ARA-290 be used in combination with erythropoietin (EPO) for enhanced neuroprotection?
▼
Combining ARA-290 with full-length erythropoietin (EPO) is not recommended because both agents bind the same tissue-protective receptor complex (EPOR-βCR), meaning they compete for the same binding site rather than producing additive effects. EPO also stimulates hematopoietic EPOR homodimers, raising hematocrit, increasing blood viscosity, and elevating thrombotic risk—adverse effects ARA-290 was specifically designed to avoid. Clinical stroke trials using high-dose EPO were terminated early due to increased mortality from thromboembolic events, even as neuroprotective efficacy was observed. The strategic advantage of ARA-290 is selective tissue protection without systemic hematologic complications, making monotherapy the preferred approach. If enhanced neuroprotection is the goal, combining ARA-290 with mechanistically distinct agents like NAC, alpha-lipoic acid, or neurotrophic peptides addresses complementary pathways without receptor competition.
What is the half-life of ARA-290 and how does it determine dosing frequency in research protocols?
▼
ARA-290 has a plasma half-life of approximately 4–6 hours following subcutaneous injection, but the duration of tissue-protective receptor activation extends significantly longer—estimated at 24–48 hours based on downstream STAT3 phosphorylation persistence in preclinical models. Clinical trials in small fiber neuropathy used a three-times-weekly dosing schedule (e.g., Monday, Wednesday, Friday) at 4mg per injection, providing overlapping receptor activation windows without requiring daily administration. This schedule balances sustained pathway engagement with patient compliance and peptide stability considerations. Continuous daily dosing has not demonstrated superiority over three-times-weekly regimens in published trials, suggesting the receptor system does not require constant ligand occupancy to maintain tissue-protective effects. For acute injury models (stroke, TBI), initial dosing occurs within hours of injury, followed by daily administration for three to seven days to cover the inflammatory expansion phase.
Does ARA-290 cross the blood-brain barrier in sufficient concentrations to protect CNS neurons?
▼
ARA-290 is an 11-amino-acid peptide with limited passive blood-brain barrier (BBB) permeability under normal physiological conditions due to its hydrophilic structure and molecular weight (~1.5 kDa). However, in pathological states—stroke, traumatic brain injury, neuroinflammation—BBB integrity is compromised, allowing increased peptide penetration into CNS parenchyma. Preclinical TBI and stroke studies confirm that systemically administered ARA-290 reduces cortical and hippocampal neuronal loss, suggesting functionally relevant CNS penetration occurs during acute injury when BBB tight junctions are disrupted. Additionally, peripheral administration of ARA-290 produces CNS effects indirectly by reducing systemic inflammatory cytokine production (IL-1β, TNF-α), which otherwise cross the BBB and activate microglia. For peripheral neuropathy applications, direct CNS penetration is unnecessary—the target neurons reside in dorsal root ganglia and peripheral nerve, both outside the BBB.
What adverse events have been reported in ARA-290 clinical trials and how do they compare to placebo?
▼
ARA-290 clinical trials in small fiber neuropathy (Phase 2 and 2b, total n=166 across studies) reported no serious adverse events directly attributable to the peptide. The most common adverse events were injection site reactions (mild erythema, transient discomfort) occurring in approximately 15% of participants, comparable to placebo injection rates. Unlike erythropoietin, ARA-290 did not elevate hematocrit, blood pressure, or markers of thrombotic risk across any dose level tested (2mg, 4mg, 8mg). No participants discontinued due to adverse events in the published trials. Preclinical toxicology studies in rodents and non-human primates at doses up to 30× the human equivalent showed no organ toxicity, behavioral changes, or histopathological abnormalities. This safety profile reflects ARA-290’s selective receptor binding—it activates tissue-protective pathways without engaging hematopoietic, vascular, or metabolic systems that mediate most peptide drug side effects.
How long does it take to see measurable neuroprotective effects from ARA-290 in peripheral neuropathy?
▼
Structural regeneration measured by intraepidermal nerve fiber density (IENFD) or corneal nerve fiber length (CNFL) requires a minimum of 28 days of consistent ARA-290 administration at therapeutic doses (4mg three times weekly), based on Phase 2 trial endpoints. Symptomatic improvement in neuropathic pain scores begins earlier—some patients report reduced burning or stabbing pain within 10–14 days, reflecting anti-inflammatory effects that precede structural regrowth. The 28-day timeline aligns with the known rate of axonal regeneration in humans, approximately 1–2 mm per day for unmyelinated C-fibers. Extending treatment to 56 days or longer may produce additional benefit in patients with severe baseline nerve loss, though no published trials have tested durations beyond eight weeks. For acute CNS injuries (stroke, TBI), neuroprotective effects manifest within hours to days—reduced lesion volume is detectable at 24–72 hours post-injury in preclinical models when ARA-290 is administered during the acute phase.
Can ARA-290 reverse established nerve damage or only prevent further progression?
▼
Clinical trial data demonstrate ARA-290 can induce measurable nerve fiber regrowth (increased IENFD) in patients with established small fiber neuropathy—this represents true regeneration, not merely halted progression. In the Maastricht University Phase 2 trial, participants had chronic SFN with mean symptom duration exceeding two years and biopsy-confirmed reduced baseline IENFD. After 28 days of ARA-290, IENFD increased by +0.59 fibers/mm from baseline, a statistically significant structural improvement that correlated with symptom reduction. However, the degree of reversibility depends on injury severity and chronicity—neurons with intact cell bodies but damaged axons can regenerate; neurons already lost to apoptosis cannot. Preclinical stroke and TBI models suggest a therapeutic window of approximately six hours for maximal salvage of acutely injured neurons, but even delayed administration (12–24 hours) provides partial protection by limiting secondary inflammatory expansion. The tissue-protective receptor remains upregulated in damaged tissue for days post-injury, allowing ARA-290 to support both acute rescue and subacute repair phases.
What makes ARA-290 different from other erythropoietin-derived peptides like CEPO or pHBSP?
▼
ARA-290 is an 11-amino-acid synthetic peptide corresponding to the helix-B surface domain of erythropoietin (EPO), the specific sequence responsible for tissue-protective receptor (EPOR-βCR) binding. CEPO (carbamylated EPO) is a chemically modified full-length EPO molecule with reduced hematopoietic activity but retained tissue protection, while pHBSP (pyroglutamate helix B surface peptide) is another EPO-derived peptide similar to ARA-290 but with N-terminal pyroglutamate modification. ARA-290’s advantage is synthetic production (no biologic manufacturing required), short sequence length (lower immunogenicity risk), and the most extensive clinical safety data of any EPO-derived tissue-protective agent. CEPO and pHBSP remain largely preclinical—few human trials exist, and manufacturing scalability is uncertain. ARA-290’s Phase 2 clinical validation and consistent preclinical performance across species and injury models make it the most advanced non-erythropoietic EPO-derived peptide for neuroprotection research.
Does ARA-290 require co-administration with any cofactors or supporting compounds for optimal efficacy?
▼
ARA-290 activates endogenous signaling pathways (JAK2/STAT3, PI3K/Akt) and does not require exogenous cofactors for receptor binding or downstream signal transduction. However, optimal tissue response to ARA-290 depends on intact cellular energy metabolism and functional intracellular signaling machinery—conditions compromised by chronic hyperglycemia, severe oxidative stress, or nutritional deficiencies. Preclinical studies suggest combining ARA-290 with metabolic support agents like alpha-lipoic acid (mitochondrial function), NAC (glutathione replenishment), or benfotiamine (thiamine cofactor for glucose metabolism) may enhance response in metabolically compromised tissue. Clinical trial protocols did not mandate cofactor supplementation, but subgroup analysis indicated patients with better baseline glycemic control (HbA1c <8%) showed more consistent IENFD increases. For research applications, ensuring adequate cellular ATP availability, redox balance, and cofactor sufficiency maximizes the tissue-protective response ARA-290 is designed to trigger.
What is the recommended storage temperature for ARA-290 and how long does it remain stable after reconstitution?
▼
Lyophilized ARA-290 powder should be stored at −20°C (standard freezer temperature) and remains stable for at least 24 months under these conditions based on manufacturer stability data. Once reconstituted with bacteriostatic water, the peptide solution must be refrigerated at 2–8°C (standard refrigerator temperature) and used within 28 days to ensure maintained potency—this timeline matches clinical trial protocols. Avoid freeze-thaw cycles once reconstituted, as repeated temperature fluctuations denature the peptide structure and reduce receptor binding affinity. For multi-dose vials, withdraw each dose using aseptic technique (alcohol swab on stopper, sterile syringe) and return the vial to refrigeration immediately. Room temperature exposure during preparation and injection (5–10 minutes) does not compromise stability, but prolonged ambient storage degrades the peptide irreversibly. Real Peptides supplies ARA-290 in lyophilized form with detailed reconstitution and storage protocols to ensure researchers maintain compound integrity throughout experimental timelines.
